




**EISAI ANNOUNCES NON-CLINICAL RESEARCH FINDINGS AT  
AACR 107TH ANNUAL MEETING REGARDING COMBINATION OF ANTICANCER  
AGENT LENVATINIB WITH EVEROLIMUS**

*ENHANCED MECHANISM OF ANGIOGENESIS INHIBITION AND  
ANTI-TUMOR ACTIVITY IN RENAL CELL CARCINOMA INVESTI*



**[Notes to editors]**

**1. About lenvatinib mesylate (generic name, “lenvatinib”, product name: Lenvima®)**

Lenvatinib is an orally administered multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2 and VEGFR3) and fibroblast growth factor (FGF) receptors (FGFR1, FGFR2, FGFR3 and FGFR4) in addition to other proangiogenic and oncogenic pathway-related RTKs (including the platelet-derived growth factor (PDGF) receptor PDGFR ; KIT; and RET) involved in tumor proliferation.

Currently, Eisai has obtained approval for lenvatinib in over 40 countries including the United States, Japan, Europe, Korea and Canada as a treatment for refractory thyroid cancer, and is undergoing regulatory review in countries throughout the world including in Asia, Russia, Australia, Brazil and Mexico. More specifically, Eisai has obtained approval for the agent indicated in the United States for